Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar DiscsMCAP MediaWire · 4 days ago
Aclarion to Present at the 20th Annual LD Micro Main EventGlobeNewsWire · Oct 13, 2026
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate EnrollmentMCAP MediaWire · Oct 8, 2026
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate EnrollmentGlobeNewsWire · Oct 8, 2026
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven SitesMCAP MediaWire · Sep 29, 2026
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven SitesGlobeNewsWire · Sep 29, 2026Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.05 | -$1.12 | Miss |
| May 21, 2026 | -$1.55 | -$1.34 | Beat |
| Feb 25, 2026 | -$3.60 | -$3.60 | Beat |
| Nov 12, 2025 | -$2.64 | -$2.93 | Miss |
| Aug 14, 2025 | -$2.26 | -$2.75 | Miss |
| May 15, 2025 | -$1,447.20 | -$9.32 | Beat |